Immunogenik, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 8R-70CAR T-cell therapy for the treatment of pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine glioma (DIPG). This designation underscores the potential of 8R‑70CAR as a first‑in‑class, targeted immunotherapy for children with no effective treatment options and reflects Immunogenik’s commitment to advancing innovative cell therapies for aggressive solid tumors.
Members of the Immunogenik team will participate in one-on-one meetings with investors and strategic partners to discuss the company’s ongoing clinical program.
University of Florida researchers have launched a first-in-human clinical trial to test a novel immunotherapy treatment for children with an aggressive type of brain tumor.
Enhance Cancer Therapeutics with 3-in-1 CAR T Cells
Advancing Cancer Therapy: Developing Antibody Blockade Targeting a Novel Immune Checkpoint, LAIR1/CD305